Experimental shot plus immunotherapy shows promise for hard-to-treat stomach cancers
NCT ID NCT06340711
First seen Apr 25, 2026 · Last updated May 25, 2026 · Updated 4 times
Summary
This study tests whether a new drug, OBP-301, injected directly into tumors, can make the immunotherapy drug pembrolizumab work better for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is PD-L1-negative or has stopped responding to immunotherapy. About 27 participants will receive five OBP-301 injections every two weeks along with pembrolizumab infusions every six weeks. The goal is to see if this combination is safe and effective in shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.